Galapagos NV
Quick facts
Phase 2 pipeline
Phase 1 pipeline
- [14]GLPG3970 oral solution
- [14C]-GLPG1205 solution for infusion
- [14C]-GLPG1690 capsules
- [14C]-GLPG1690 solution for infusion
- [14C]-GLPG1972 oral solution
- [14C]-GLPG1972 solution for infusion
- [14C]-GLPG3667 capsule
- [14C]-GLPG3667 solution for infusion
- [14C]GLPG3970 solution for infusion
- Cocktail of CYP450 substrates
- GLPG0187
- GLPG0259 free base
- GLPG0555
- GLPG0555 aqueous
- GLPG0555 nanosuspension
- GLPG0555 solid dispersion
- GLPG0778
- GLPG1205 capsules
- GLPG1205 film-coated tablets
- GLPG1690 film-coated tablets
- GLPG1690 single ascending doses
- GLPG1837 multiple ascending doses
- GLPG1837 single ascending doses
- GLPG1972 - A
- GLPG1972 - B
- GLPG1972 - C
- GLPG1972 film-coated tablets
- GLPG1972 multiple ascending doses
- GLPG1972 single ascending doses
- GLPG2222
- GLPG2222 multiple doses
- GLPG2222 single dose
- GLPG2451 dose regimen A
- GLPG2451 dose regimen B
- GLPG2451 multiple dose
- GLPG2451 single dose
- GLPG2737 multiple dose
- GLPG2737 single dose
- GLPG3067 multiple dose
- GLPG3067 oral suspension
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: